Shape Therapeutics’ Big Financing Shows Growing Interest In Novel Capsids

Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.

Horizontal image of a collection of prescription capsules and tablets in the shape of DNA running diagonally across the picture on a light green background with room for copy (text).
Shape Therapeutics said it raised $116m in a series B venture capital round • Source: Shutterstock

Shape Therapeutics, Inc. is the latest gene therapy-focused company to raise a large amount of capital with the aim of developing adeno-associated viral (AAV) vector-based gene therapies that offer improvements over existing products.

Seattle-based ShapeTx said on 15 July that it completed a $112m series B venture capital round, which it plans to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.